Cathepsin C Inhibitors: Property Optimization and Identification of a Clinical Candidate.
Furber, M., Gardiner, P., Tiden, A.K., Mete, A., Ford, R., Millichip, I., Stein, L., Mather, A., Kinchin, E., Luckhurst, C., Barber, S., Cage, P., Sanganee, H., Austin, R., Chohan, K., Beri, R., Thong, B., Wallace, A., Oreffo, V., Hutchinson, R., Harper, S., Debreczeni, J., Breed, J., Wissler, L., Edman, K.(2014) J Med Chem 57: 2357
- PubMed: 24592859 
- DOI: https://doi.org/10.1021/jm401705g
- Primary Citation of Related Structures:  
4CDC, 4CDD, 4CDE, 4CDF - PubMed Abstract: 
A lead generation and optimization program delivered the highly selective and potent CatC inhibitor 10 as an in vivo tool compound and potential development candidate. Structural studies were undertaken to generate SAR understanding.
Organizational Affiliation: 
AstraZeneca , Pepparedsleden 1, Mölndal 431 83, Sweden.